Head-to-head evidence
cagrilintide/semaglutide vs CJC-1134-PC
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Type 2 Diabetes
Shared mechanism: GLP-1 receptor · full Type 2 Diabetes pipeline
cagrilintide/semaglutide · CagriSema
Developed by Novo Nordisk
NCT05394519 · Phase 3 · completed
This was a large, randomized, quadruple-blind, placebo-controlled trial in 1,200 patients using percentage body weight change, the standard efficacy measure for obesity treatment. CagriSema reduced body weight by 13.7% versus 3.4% on placebo, a 10.4-percentage-point difference (p<0.001), meeting the primary endpoint.
Next expected readout: June 2027 · NCT07817251 (registry estimate)
CJC-1134-PC
Developed by ConjuChem
NCT07058545 · Phase 3 · completed
The study randomized 474 participants to CJC-1134-PC or placebo and blinded participants, care providers, investigators, and outcome assessors. Its primary endpoint was change in HbA1c at Week 25, a surrogate measure, and the registry does not report whether the comparison was favorable or statistically significant.
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: cagrilintide/semaglutide's landscape · CJC-1134-PC's landscape